Fundraising FoxTearClear, Inc.
Copley, US · Founded 2015 · Delaware corporation · 3 known investors
Find your way into TearClear, Inc.
Sign up to see every warm intro you have to TearClear, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the TearClear, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
Board
WL
William LinkBoard directorManaging Partner at Flying L Partners
JW
Jeffry WeinhuffBoard directorManaging Partner at Visionary Ventures
TS
Tyler StowaterBoard director
RH
Richard HeinickBoard director
SP
Steve PazolBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$52.4M disclosed across 6 rounds · 2017–2023
▶$11.8MraisedJul 2023 · 70 investors · PharmaceuticalsRule 506(b)
▶$11.8MraisedJul 2023 · 70 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Richard HeinickDirector
- Tyler StowaterDirector
- Stuart RaetzmanDirector
- Srini VenkateshExecutive Officer
- Richard HarrisonExecutive Officer
- William LinkDirector
- Jeffry WeinhuffDirector
- Offering amount
- $16M
- Amount sold
- $11.8M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.9MraisedAug 2022 · 43 investors · PharmaceuticalsRule 506(b)
▶$5.9MraisedAug 2022 · 43 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert BaileyDirector
- Kevin HershfieldExecutive Officer
- Richard HeinickDirector
- Tyler StowaterDirector
- Jeffry WeinhuffDirector
- Stuart RaetzmanExecutive Officer, Director
- William LinkDirector
- Offering amount
- $10M
- Amount sold
- $5.9M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$22.3MraisedAug 2020 · 51 investors · PharmaceuticalsRule 506(b)
▶$22.3MraisedAug 2020 · 51 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Tyler StowaterDirector
- Steve PazolDirector
- Kevin HershfieldExecutive Officer
- William LinkDirector
- Robert DempseyExecutive Officer, Director
- Richard HeinickDirector
- Jeffry WeinhuffDirector
- Offering amount
- $26M
- Amount sold
- $22.3M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$2.8MraisedFeb 2020 · 32 investors · PharmaceuticalsRule 506(b)
▶$2.8MraisedFeb 2020 · 32 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Richard HeinickDirector
- Kevin HershfieldExecutive Officer, Director
- William LinkDirector
- Steve PazolDirector
- Jeffry WeinhuffDirector
- Tyler StowaterDirector
- Offering amount
- $3M
- Amount sold
- $2.8M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$5MraisedFeb 2019 · 22 investors · BiotechnologyRule 506(b)
▶$5MraisedFeb 2019 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tyler StowaterDirector
- William LinkDirector
- Steve PazolDirector
- Kevin HershfieldExecutive Officer, Director
- Jeffry WeinhuffDirector
- Richard HeinickDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$4.6MraisedMay 2017 · 11 investors · BiotechnologyRule 506(b)
▶$4.6MraisedMay 2017 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William LinkDirector
- Kevin HershfieldExecutive Officer, Director
- Richard HeinickDirector
- Steve PazolDirector
- Jeffry WeinhuffDirector
- Tyler StowaterDirector
- Offering amount
- $4.6M
- Amount sold
- $4.6M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
TearSolutionsTearSolutions develops Lacripep, a topical peptide therapy derived from the Lacritin protein for the treatment of dry eye disease, including cases associated with primary Sjögren's Syndrome. The company is running clinical trials of the drug candidate for patients with moderate to severe dry eye.
OphthalmologytimesOphthalmology Times is a medical news publication covering clinical research, drug approvals, and treatment developments in eye care for ophthalmologists and other eye care professionals. It publishes articles, videos, podcasts, a digital edition, and continuing medical education content.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies working in the same space as TearClear, Inc..
In the news
Frequently asked questions
- Who are TearClear, Inc.'s investors?
- TearClear, Inc.'s investors include Flying L Partners, Visionary Ventures, Versant Venture AIV Holdings.
- How much funding has TearClear, Inc. raised?
- TearClear, Inc. has disclosed $52.4M raised across 6 rounds.
- Where is TearClear, Inc. headquartered?
- TearClear, Inc. is headquartered in Copley, US.